Key factors to consider when selecting an anti-IL23p19 agent include patient preference regarding mode of administration, IBD phenotype, presence of coexisting extra-intestinal manifestations, concomitant immune-mediated diseases, and previous advanced-therapy exposure. The gene discussed is IL23A; the disease is inflammatory bowel disease.